Bibliography
- Holick MF. Vitamin D Deficiency. N Engl J Med 2007;357:266-81
- DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004;80:1689S-96S
- Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005;26:662-87
- Makishima M, Yamada S. Targeting the vitamin D receptor: advances in drug discovery. Expert Opin Ther Pat 2005;15:1133-45
- Makishima M. Nuclear receptors as targets for drug development: regulation of cholesterol and bile acid metabolism by nuclear receptors. J Pharmacol Sci 2005;97:177-83
- Rosenfeld MG, Lunyak VV, Glass CK. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev 2006;20:1405-28
- Kim MS, Fujiki R, Kitagawa H, Kato S. 1α,25(OH)2D3-induced DNA methylation suppresses the human CYP27B1 gene. Mol Cell Endocrinol 2007;265-266:168-73
- Kato S, Fujiki R, Kim MS, Kitagawa H. Ligand-induced transrepressive function of VDR requires a chromatin remodeling complex, WINAC. J Steroid Biochem Mol Biol 2007;103:372-80
- Carlberg C, Dunlop TW, Saramaki A, et al. Controlling the chromatin organization of vitamin D target genes by multiple vitamin D receptor binding sites. J Steroid Biochem Mol Biol 2007;103:338-43
- Haussler MR, Whitfield GK, Haussler CA, et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 1998;13:325-49
- Thummel KE, Brimer C, Yasuda K, et al. Transcriptional control of intestinal cytochrome P-4503A by 1α,25-dihydroxy vitamin D3. Mol Pharmacol 2001;60:1399-406
- Saramaki A, Banwell CM, Campbell MJ, Carlberg C. Regulation of the human p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor. Nucl Acids Res 2006;34:543-54
- Sinkkonen L, Malinen M, Saavalainen K, et al. Regulation of the human cyclin C gene via multiple vitamin D3-responsive regions in its promoter. Nucl Acids Res 2005;33:2440-51
- Matilainen M, Malinen M, Saavalainen K, Carlberg C. Regulation of multiple insulin-like growth factor binding protein genes by 1α,25-dihydroxyvitamin D3. Nucl Acids Res 2005;33:5521-32
- Kim MS, Fujiki R, Murayama A, et al. 1α,25(OH)2D3-induced transrepression by vitamin D receptor through E-box-type elements in the human parathyroid hormone gene promoter. Mol Endocrinol 2007;21:334-42
- Brown AJ, Dusso AS, Slatopolsky E. Vitamin D analogues for secondary hyperparathyroidism. Nephrol Dial Transplant 2002;17:10-9
- Carlberg C. Molecular basis of the selective activity of vitamin D analogues. J Cell Biochem 2003;88:274-81
- Makishima M, Lu TT, Xie W, et al. Vitamin D receptor as an intestinal bile acid sensor. Science 2002;296:1313-6
- Okano T, Tsugawa N, Masuda S, et al. Regulatory activities of 2β-(3-hydroxypropoxy)-1α, 25-dihydroxyvitamin D3, a novel synthetic vitamin D3 derivative, on calcium metabolism. Biochem Biophys Res Commun 1989;163:1444-9
- Okano T, Tsugawa N, Masuda S, et al. Protein-binding properties of 22-oxa-1α,25-dihydroxyvitamin D3, a synthetic analogue of 1α,25-dihydroxyvitamin D3. J Nutr Sci Vitaminol 1989;35:529-33
- Brown AJ, Finch J, Grieff M, et al. The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine. Endocrinology 1993;133:1158-64
- Choi M, Yamamoto K, Itoh T, et al. Interaction between vitamin D receptor and vitamin D ligands: two-dimensional alanine scanning Mutational Analysis. Chem Biol 2003;10:261-70
- Takeyama K, Masuhiro Y, Fuse H, et al. Selective interaction of vitamin D receptor with transcriptional coactivators by a vitamin D analog. Mol Cell Biol 1999;19:1049-55
- Abe J, Nakamura K, Takita Y, et al. Prevention of immunological disorders in MRL/l mice by a new synthetic analogue of vitamin D3: 22-oxa-1α,25-dihydroxyvitamin D3. J Nutr Sci Vitaminol 1990;36:21-31
- Koike N, Hayakawa N, Tokuda K, et al. In vivo time-course of receptor binding in the parathyroid gland of the vitamin D analogue [3H]1, 25-dihydroxy-22-oxavitamin D3 compared with [3H]1,25-dihydroxyvitamin D3, determined by micro-autoradiography. Nephrol Dial Transplant 2002;17:53-7
- Li M, Hener P, Zhang Z, et al. Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis. Proc Natl Acad Sci USA 2006;103:11736-41
- Sprague SM, Llach F, Amdahl M, et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003;63:1483-90
- Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-83
- Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-56
- Kumagai T, O'Kelly J, Said JW, Koeffler HP. Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells. J Natl Cancer Inst 2003;95:896-905
- Tanaka Y, Nakamura T, Nishida S, et al. Effects of a synthetic vitamin D analog, ED-71, on bone dynamics and strength in cancellous and cortical bone in prednisolone-treated rats. J Bone Miner Res 1996;11:325-36
- Okuda N, Takeda S, Shinomiya K, et al. ED-71, a novel vitamin D analog, promotes bone formation and angiogenesis and inhibits bone resorption after bone marrow ablation. Bone 2007;40:281-92
- Kubodera N, Tsuji N, Uchiyama Y, Endo K. A new active vitamin D analog, ED-71, causes increase in bone mass with preferential effects on bone in osteoporotic patients. J Cell Biochem 2003;88:286-9
- Matsumoto T, Miki T, Hagino H, et al. A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 2005;90:5031-6
- Sicinski RR, Prahl JM, Smith CM, Deluca HF. New 1α,25-dihydroxy-19-norvitamin D3 compounds of high biological activity: synthesis and biological evaluation of 2-hydroxymethyl, 2-methyl, and 2-methylene analogues. J Med Chem 1998;41:4662-74
- Shevde NK, Plum LA, Clagett-Dame M, et al. A potent analog of 1α,25-dihydroxyvitamin D3 selectively induces bone formation. Proc Natl Acad Sci USA 2002;99:13487-91
- Thomson B, Ahrens JM, Ntambi JM, et al. 2-Methylene-19-nor-1α-hydroxyvitamin D3 analogs inhibit adipocyte differentiation and PPARγ2 gene transcription. Arch Biochem Biophys 2007;460:192-201
- Schwinn MK, DeLuca HF. Differential recruitment of coactivators to the vitamin D receptor transcriptional complex by 1α,25-dihydroxyvitamin D3 analogs. Arch Biochem Biophys 2007;465:443-51
- Vanhooke JL, Benning MM, Bauer CB, et al. Molecular structure of the rat vitamin D receptor ligand binding domain complexed with 2-carbon-substituted vitamin D3 hormone analogues and a LXXLL-containing coactivator peptide. Biochemistry 2004;43:4101-10
- Yamamoto H, Shevde NK, Warrier A, et al. 2-Methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3 potently stimulates gene-specific DNA binding of the vitamin D receptor in osteoblasts. J Biol Chem 2003;278:31756-65
- Plum LA, Prahl JM, Ma X, et al. Biologically active noncalcemic analogs of 1α,25-dihydroxyvitamin D with an abbreviated side chain containing no hydroxyl. Proc Natl Acad Sci USA 2004;101:6900-4
- Williams KB, DeLuca HF. 2-Methylene-19-nor-20(S)-1α-hydroxy-bishomopregnacalciferol [20(S)-2MbisP], an analog of vitamin D3 [1,25(OH)2D3], does not stimulate intestinal phosphate absorption at levels previously shown to suppress parathyroid hormone. Steroids 2008;73:1277-84
- Slatopolsky E, Finch JL, Brown AJ, et al. Effect of 2-methylene-19-nor-(20S)-1α-hydroxy-bishomopregnacalciferol (2MbisP), an analog of vitamin D, on secondary hyperparathyroidism. J Bone Miner Res 2007;22:686-94
- Albert DM, Plum LA, Yang W, et al. Responsiveness of human retinoblastoma and neuroblastoma models to a non-calcemic 19-nor Vitamin D analog. J Steroid Biochem Mol Biol 2005;97:165-72
- Peleg S, Uskokovic M, Ahene A, et al. Cellular and molecular events associated with the bone-protecting activity of the noncalcemic vitamin D analog Ro-26-9228 in osteopenic rats. Endocrinology 2002;143:1625-36
- Ismail A, Nguyen CV, Ahene A, et al. Effect of cellular environment on the selective activation of the vitamin D receptor by 1α,25-Dihydroxyvitamin D3 and its analog 1α-fluoro-16-ene-20-epi-23-ene-26,27-bishomo-25-hydroxyvitamin D3 (Ro-26-9228). Mol Endocrinol 2004;18:874-87
- Vaisanen S, Perakyla M, Karkkainen JI, et al. Structural evaluation of the agonistic action of a vitamin D analog with two side chains binding to the nuclear vitamin D receptor. Mol Pharmacol 2003;63:1230-7
- Carlberg C, Mourino A. New vitamin D receptor ligands. Expert Opin Ther Pat 2003;13:761-72
- Norman AW, Manchand PS, Uskokovic MR, et al. Characterization of a novel analogue of 1α,25(OH)2-vitamin D3 with two side chains: interaction with its nuclear receptor and cellular actions. J Med Chem 2000;43:2719-30
- Gonzalez MM, Samenfeld P, Perakyla M, Carlberg C. Corepressor excess shifts the two-side chain vitamin D analog Gemini from an agonist to an inverse agonist of the vitamin D receptor. Mol Endocrinol 2003;17:2028-38
- Spina C, Tangpricha V, Yao M, et al. Colon cancer and solar ultraviolet B radiation and prevention and treatment of colon cancer in mice with vitamin D and its Gemini analogs. J Steroid Biochem Mol Biol 2005;l97:111-20
- Ishizuka S, Miura D, Ozono K, et al. Antagonistic actions in vivo of (23S)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone on calcium metabolism induced by 1α,25-dihydroxyvitamin D3. Endocrinology 2001;142:59-67
- Inaba Y, Yamamoto K, Yoshimoto N, et al. Vitamin D3 derivatives with adamantane or lactone ring side chains are cell type-selective vitamin D receptor modulators. Mol Pharmacol 2007;71: 1298-311
- Ma Y, Khalifa B, Yee YK, et al. Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators. J Clin Invest 2006;116: 892-904
- Perakyla M, Malinen M, Herzig KH, Carlberg C. Gene regulatory potential of nonsteroidal vitamin D receptor ligands. Mol Endocrinol 2005;19:2060-73
- Hofmann AF. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 1999;159:2647-58
- Adachi R, Shulman AI, Yamamoto K, et al. Structural determinants for vitamin D receptor response to endocrine and xenobiotic signals. Mol Endocrinol 2004;18:43-52
- Yamamoto K, Abe D, Yoshimoto N, et al. Vitamin D receptor: ligand recognition and allosteric network. J Med Chem 2006;49:1313-24
- Ishizawa M, Matsunawa M, Adachi R, et al. Lithocholic acid derivatives act as selective vitamin D receptor modulators without inducing hypercalcemia. J Lipid Res 2008;49:763-72
- Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006;311:1770-3
- Nijenhuis T, Hoenderop JG, Bindels RJ. TRPV5 and TRPV6 in Ca(2+) (re)absorption: regulating Ca(2+) entry at the gate. Pflugers Arch 2005;451:181-92
- Kutuzova GD, Akhter S, Christakos S, et al. Calbindin D9k knockout mice are indistinguishable from wild-type mice in phenotype and serum calcium level. Proc Natl Acad Sci USA 2006;103:12377-81
- Hoenderop JGJ, van Leeuwen JPTM, van der Eerden BCJ, et al. Renal Ca2+ wasting, hyperabsorption, and reduced bone thickness in mice lacking TRPV5. J Clin Invest 2003;112:1906-14
- Bianco SDC, Peng JB, Takanaga H, et al. Marked disturbance of calcium homeostasis in mice with targeted disruption of the Trpv6 calcium channel gene. J Bone Miner Res 2007;22:274-85
- Kutuzova GD, Sundersingh F, Vaughan J, et al. TRPV6 is not required for 1α,25-dihydroxyvitamin D3-induced intestinal calcium absorption in vivo. Proc Natl Acad Sci USA 2008;105:19655-9
- Sakaki T, Sawada N, Abe D, et al. Metabolism of 26,26,26,27,27,27-F6-1α,25-dihydroxyvitamin D3 by CYP24: species-based difference between humans and rats. Biochem Pharmacol 2003;65:1957-65
- Committee NRN. A unified nomenclature system for the nuclear receptor superfamily. Cell 1999;97:161-3
- Whitfield GK, Dang HTL, Schluter SF, et al. Cloning of a functional vitamin D receptor from the lamprey (Petromyzon marinus), an ancient vertebrate lacking a calcified skeleton and teeth. Endocrinology 2003;144:2704-16
- Nehring JA, Zierold C, DeLuca HF. Lithocholic acid can carry out in vivo functions of vitamin D. Proc Natl Acad Sci USA 2007;104:10006-9